If I Can't Talk You Into Buying AMC This Summer, How About Cinemark, IMAX, or EPR?

U.S. box office ticket sales have reached $3.7 billion year to date, up 10% from a year ago and 40% from two years ago, marking the strongest five-month start since the pandemic. Analysts expect AMC and Cinemark revenue growth of 11% to 12% this year, while Cinemark is already profitable and trading at under 14x forward earnings versus AMC's ongoing losses. The article also highlights IMAX's 23x forward earnings valuation and EPR Properties' 6.4% dividend yield as alternative ways to play the theater recovery.

Analysis

The real trade here is not “movies are back,” but that the recovery is finally becoming selective. Higher attendance helps all operators, yet the balance of power is shifting toward the names with cleaner balance sheets and less equity overhang: they get the same revenue tailwind without AMC’s dilution tax. That creates a second-order winner/loser setup where improving box office data can lift the whole group, but the beta should accrue disproportionately to CNK and IMAX, while AMC remains a capital structure story first and an operating story second.

AMC’s problem is that even a durable box office rebound may not translate into meaningful per-share value in the near term. If the company needs several years to reach real earnings power, the market can keep using equity issuance or refinancing terms to suppress upside, especially if rates stay restrictive and lease obligations remain sticky. The key catalyst risk is that better attendance invites management to “monetize” the recovery with more dilution or opportunistic capital raises, which would mechanically transfer the upside away from common holders.

IMAX is the cleaner way to express a blockbuster mix-upcycle without betting on a single exhibitor’s economics. The more interesting contrarian angle is that the current hit slate suggests theatrical demand may be broadening beyond event films, which is a better sign for multiplex traffic than for any one premium-format vendor; in that world, CNK benefits most because its valuation is still anchored to a normal earnings recovery rather than a venture-style narrative. For EPR, the key is that theater strength lowers near-term tenant stress, but the stock still behaves like a duration-sensitive yield instrument; if rates stay elevated, the distribution may support the shares more than growth does.

Key Decisions for Investors

• Long CNK / short AMC for 3-6 months: express the view that recovery accrues to the operator with a sane equity base and visible earnings, while AMC’s upside remains capped by dilution and refinancing risk.
• Buy IMAX on pullbacks for a 6-12 month hold: use it as a higher-quality theater beta with better earnings leverage and less direct exposure to concession margin compression.
• Sell AMC out-of-the-money call spreads into any box-office-driven squeeze over the next 4-8 weeks: the stock can rally on sentiment, but financing risk should cap sustained upside.
• Long EPR only as a yield-plus-stability trade for 6-12 months, but size modestly: the thesis works if rates drift lower; if the 10-year re-prices up, the multiple can compress despite healthier tenants.
• Watch for any AMC capital raise or lease renegotiation headline as the reversal trigger: that would be a signal to reduce exposure across the theater basket, since it would likely reset the recovery trade lower.